1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,000 | 9,050 | 13:03 | |
| 8,950 | 9,200 | 31.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | Fortrea launches $75.7 million debt tender offer for senior notes | 1 | Investing.com | ||
| 20.10. | Fortrea Holdings Inc: Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt | 2 | GlobeNewswire (USA) | ||
| 02.10. | Where Fortrea Holdings Stands With Analysts | 9 | Benzinga.com | ||
| 22.09. | Fortrea names William Sharbaugh to board of directors | 2 | Investing.com | ||
| 22.09. | Fortrea beruft William Sharbaugh in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 22.09. | Fortrea Holdings Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| 22.09. | Fortrea Holdings Inc: Fortrea Appoints William Sharbaugh to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 12.09. | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 133 | GlobeNewswire (Europe) | DURHAM, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization, today announced the granting of an inducement award of restricted... ► Artikel lesen | |
| FORTREA Aktie jetzt für 0€ handeln | |||||
| 05.09. | Hedge Fund and Insider Trading News: Bill Ackman, John Paulson, Warren Buffett, Third Point, Starboard Value, Fortrea Holdings Inc (FTRE), Microsoft Corp (MSFT), and More | 31 | Insider Monkey | ||
| 03.09. | Demystifying Fortrea Holdings: Insights From 6 Analyst Reviews | 5 | Benzinga.com | ||
| 01.09. | Fortrea Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 12 | SEC Filings | ||
| 27.08. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.08. | Jefferies raises Fortrea stock price target to $7 on cleaner income statement | 8 | Investing.com | ||
| 07.08. | Fortrea raises 2025 revenue guidance to $2.6B-$2.7B amid CEO transition and margin optimization | 3 | Seeking Alpha | ||
| 06.08. | Fortrea Holdings Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 06.08. | Fortrea Holdings Non-GAAP EPS of $0.19, revenue of $710.3M | 3 | Seeking Alpha | ||
| 06.08. | Fortrea Q2 2025 slides: Revenue growth accelerates as new CEO takes helm | 3 | Investing.com | ||
| 06.08. | Fortrea Q2 2025: Umsatzwachstum beschleunigt sich unter neuer Führung | 6 | Investing.com Deutsch | ||
| 06.08. | Fortrea Holdings Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.08. | Fortrea Holdings Inc: Fortrea Reports Second Quarter 2025 Results | 298 | GlobeNewswire (Europe) | For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 millionGAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA... ► Artikel lesen |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 44,550 | +0,56 % | BB Biotech überzeugt mit starkem Quartal | Die Schweizer Beteiligungsgesellschaft legt einen beeindruckenden Lauf hin. BB Biotech (ISIN CH0038389992) steigerte im dritten Quartal den Nettoinventarwert um 24 Prozent in Franken. Der Aktienkurs... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| AMGEN | 258,00 | +0,12 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,227 | -0,92 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| STRYKER | 308,30 | -0,29 % | Stryker Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed earnings for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings came in... ► Artikel lesen | |
| ILLUMINA | 107,18 | -0,24 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,00 | +0,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| AAP IMPLANTATE | 1,410 | -4,08 % | aap Implantate steigert Quartalsumsatz um 15 Prozent | Die aap Implantate AG hat im dritten Quartal 2025 den Umsatz um 15 Prozent gegenüber dem Vorjahreszeitraum gesteigert. Das Unternehmen profitierte nach eigenen Angaben vom Dienstag vor allem von der... ► Artikel lesen | |
| OCUGEN | 1,370 | +1,60 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,517 | -1,45 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call | ||
| INTELLIA THERAPEUTICS | 11,060 | -0,36 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 78,50 | +0,64 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,460 | -4,76 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| EDITAS MEDICINE | 2,717 | +1,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
Das Unternehmen FORTREA HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,150 (+1,65 %) liegt der Kurs bei 9,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTREA HOLDINGS INC finden Sie auf Wallstreet Online.